Romidepsin solid forms and uses thereof

Abstract

The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.

1 . Crystalline Form C of romidepsin.  
     
     
         2 . Crystalline Form D of romidepsin.  
     
     
         3 . Crystalline Form E of romidepsin.  
     
     
         4 . Crystalline Form F of romidepsin.  
     
     
         5 . Crystalline Form H of romidepsin.  
     
     
         6 . Crystalline Form I of romidepsin.  
     
     
         7 . Crystalline Form J of romidepsin.  
     
     
         8 . Crystalline Form K of romidepsin.  
     
     
         9 . Crystalline Form L of romidepsin.  
     
     
         10 . Crystalline Form N of romidepsin.  
     
     
         11 . A composition, comprising romidepsin, wherein substantially all of the romidepsin is amorphous.  
     
     
         12 . The composition of  claim 11 , wherein the composition has an XRPD pattern substantially similar to  FIG. 7 ( a ).  
     
     
         13 . The composition of  claim 11 , wherein the amorphous romidepsin is obtained from a water/dichloromethane mixture, or an isopropanol-trifluoroethanol/methanol mixture.  
     
     
         14 . A composition, comprising amorphous romidepsin and povidone.  
     
     
         15 . The composition of  claim 14 , wherein the povidone is povidone USP.  
     
     
         16 . The composition of  claim 14 , wherein the povidone is povidone EP.  
     
     
         17 . The composition of any one of  claim 14  to  16 , wherein the ratio of amorphous romidepsin to povidone is about 1:2.  
     
     
         18 . A method of treating a hematological disorder comprising administering to a subject the composition of  claim 17 .  
     
     
         19 . The method of  claim 18 , wherein the hematological disorder is peripheral T cell lymphoma (PTCL).  
     
     
         20 . The method of  claim 18 , wherein the hematological disorder is cutaneous T cell lymphoma (CTCL).